Why this exciting ASX biotech stock could be a future star

Bell Potter thinks this high-flying biotech stock could generate more big returns.

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Clarity Pharmaceuticals Ltd (ASX: CU6) shares have been on fire over the last 12 months.

During this time the ASX biotech stock has rocketed a massive 280%.

To put that into context, a $20,000 investment in the radiopharmaceuticals company a year ago would now be worth $56,000 today.

But the good news is that one leading broker believes these gains could continue.

What is the broker saying about this ASX biotech stock?

Bell Potter highlights that global healthcare giant Astra Zeneca has just acquired one of Clarity's radiopharmaceuticals rivals.

It sees a lot of positives in the deal and notes the significant premium that Astra Zeneca paid. The broker said:

Astra Zeneca (AZ) will acquire the NASDAQ listed Fusion Pharmaceuticals for up to US$2.4bn. The largely cash deal represents a 126% premium for Fusion shareholders and yet another validation of radiopharmaceuticals as an emerging cornerstone in oncology. AZ has a well established oncology franchise and the acquisition is a logical extension to its portfolio. The transactions also has clear implications for the implied valuation of CU6.

Given the similarities of the two companies, Bell Potter appears to believe that this ASX biotech stock could be of interest to other giants wanting exposure to radiopharmaceuticals. It said:

Fusion appears to be at a similar development stage to Clarity in mCRPC i.e. dose determination and in planning for a pivotal study. Both companies have produced encouraging case study data arising from patients involved in earlier clinical trials. We concluded that the level of interest among pharma groups looking for radiopharmaceutical assets remains at fever pitch. This acquisition by AZ is the third transaction in recent months involving a top tier pharma in the category. High quality, later stage assets are likely to continue to attract premium prices.

More returns to come

In response to the news, Bell Potter has reiterated its speculative buy rating and $3.90 price target on the ASX biotech stock.

This implies potential upside of 32% for investors over the next 12 months.

So, while it may have almost quadrupled in value since this time last year, clearly Bell Potter doesn't believe it is too late to invest (if you have a high risk tolerance).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended AstraZeneca Plc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

a mine worker holds his phone in one hand and a tablet in the other as he stands in front of heavy machinery at a mine site.
Resources Shares

Goldman Sachs says this ASX 200 mining share is in for a 33% whack

The top broker predicts a fairly miserable 12 months ahead for this diversified miner.

Read more »

A woman wearing a top of gold coins and large gold hoop earrings and a heavy gold bracelet stands amid a shower of gold coins with her mouth open wide and an excited look on her face.
Opinions

I believe this ASX 200 stock can DOUBLE its profit in 5 years

This stock has enormous profit growth potential in my eyes, here’s why.

Read more »

Top ten gold trophy.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors endured a sour end to the trading week today.

Read more »

Lion holding and screaming into a yellow loudspeaker on a blue background, symbolising an announcement from Liontown.
Opinions

3 ASX shares that could walk away winners from the 'Future Made in Australia Act'

Life is a whole lot easier when money is being thrown your way.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Dividend Investing

With 8%+ dividends, how long can these ASX 200 passive income shares stay cheap?

I think ASX 200 investors looking for ‘cheap’ passive income shares will want to check these out.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Avita Medical, Cettire, Domino's Pizza, and Star shares are falling today

These ASX shares are having a tough end to the week. But why?

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Boral, FBR, Origin, and Regis Resources shares are pushing higher today

These ASX shares are ending the week positively. But why?

Read more »